High-Grade Serous Ovarian Cancer — Trials

High-Grade Serous Ovarian Cancer — Trials · CancerIndex

Clinical trials

Registered studies

28 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 13
Recruiting: 8
Ph III recruiting: 1
Growth YoY: —
Industry share: 46%
Top sponsor: University Health Network, Toronto
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07791732	A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)	not yet recruiting	Phase 3	600	Daiichi SankyoINDUSTRY	0	Sep 1, 2026	clinicaltrials
NCT07432594	Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer	not yet recruiting	Phase 2	82	Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER